Abstract: A method comprising creating and storing a graph having nodes and edges that represent financial assets and accounts in which the assets are held; individuals who own the assets; or legal entities who own the assets; receiving and storing bucketing factors and column factors; traversing the graph and creating a list of a plurality of paths of nodes and edges in the graph; applying the bucketing factors to the paths to result in associating each set among a plurality of sets of the nodes with a different value node among a plurality of value nodes; applying the column factors to the paths and the value nodes to result in associating column result values with the value nodes; creating and causing displaying a table view by forming rows based on the value nodes and forming columns based on the column result values.

Abstract: The present disclosure provides a wiring device having a color change kit. The color change kit includes a removable skirt and switch cover. The skirt and switch cover, which are disposed on the wiring device and accessible by an end-user, are easily detachable from the wiring device. Thus, the skirt and the switch cover are replaced without replacing the entire wiring device. Further, the skirt and switch cover is replaced without removing the wiring device from a wall box or further disassembling the entire wiring device. In certain exemplary embodiments, the skirt is disposed within a housing of the wiring device, and the switch cover is disposed within the skirt.

Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.

Abstract: The present disclosure provides a wiring device having a color change kit. The color change kit includes a removable skirt and switch cover. The skirt and switch cover, which are disposed on the wiring device and accessible by an end-user, are easily detachable from the wiring device. Thus, the skirt and the switch cover are replaced without replacing the entire wiring device. Further, the skirt and switch cover is replaced without removing the wiring device from a wall box or further disassembling the entire wiring device. In certain exemplary embodiments, the skirt is disposed within a housing of the wiring device, and the switch cover is disposed within the skirt.

Abstract: A method comprising creating and storing a graph having nodes and edges that represent financial assets and accounts in which the assets are held; individuals who own the assets; or legal entities who own the assets; receiving and storing bucketing factors and column factors; traversing the graph and creating a list of a plurality of paths of nodes and edges in the graph; applying the bucketing factors to the paths to result in associating each set among a plurality of sets of the nodes with a different value node among a plurality of value nodes; applying the column factors to the paths and the value nodes to result in associating column result values with the value nodes; creating and causing displaying a table view by forming rows based on the value nodes and forming columns based on the column result values.

Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.

Abstract: The invention relates to the liquid and lyophilized formulations of small particulates, liposomes, and micelles, and methods for making and using the formulations. In particular, at least in some embodiments, the present invention relates to the production and lyophilization of PEGylated nanoparticles, microparticles, micelles, and liposomes for use and administration in to a subject.

Abstract: An ophthalmic composition containing solubilized cyclosporin is able to be obtained in the presence of at least one 1,2-alkanediol having 5 to 7 carbon atoms and at least one polysorbate surface active agent in an ophthalmically acceptable medium. The composition is stable without crystallization and/or precipitation of cyclosporin. The composition is suitable for treatment of ophthalmic disorders including keratoconjectivis Sicca and ocular rosacea.

Abstract: Described are aqueous topical compositions containing a combination of benzoyl peroxide, at least one dicarboxylic acid having 6 to 12 carbon atoms, and at least one vitamin B.sub.3 compound in aqueous vehicles containing at least one 1,2-alkanediol having from 5 to 7 carbon atoms. The compositions are suitable for treatment of acne. Also described are methods for topically delivering a medicament to a human patient, in need of the medicament by topically administering to the patient the compositions of the present invention.

Abstract: Topical compositions containing at least one solubilized dicarboxylic acid having 6 to 12 carbon atoms are prepared in pharmaceutically acceptable carriers in the presence of at least one 1,2-alkanediol having 5 to 7 carbon atoms. In particular, a topical composition containing solubilized azelaic acid is formulated in an aqueous carrier. In-vitro skin penetration and bioavailability study demonstrates higher bioavailability of the solubilized azelaic acid in the cutaneous organs. The topical composition is advantageous in treatment of skin disorders associated with skin inflammation such as rosacea, seborrheic dermatitis, perioral dermatitis, and facial dermatitis.

Abstract: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, first one is niacinamide, second one is urea, and third one is hydroxyalkyl urea. Related methods are also disclosed.

Abstract: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, one of which is urea and the other is hydroxyalkyl urea. Related methods are also disclosed.

Abstract: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, one of which is niacinamide and the other is hydroxyalkyl urea. Related methods are also disclosed.

Abstract: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, one of which is niacinamide and the other is urea. Related methods are also disclosed.

Abstract: Substantially homogeneous topical preparations for cosmetic, veterinary, and pharmaceutical use comprise at least one active ingredient solubilized in a novel composition base. The composition base comprises solubilized allantoin at a level of at least 0.5% and urea at a level of at least 10% in an aqueous vehicle.

Abstract: This invention relates to topical compositions in the form of dispersion gels formed by dispersing into an aqueous gel phase a substantially homogenous organic solution containing at least one active ingredient and at least one organic polymer solubilized in an organic carrier. The organic carrier comprises at least one water-miscible organic solvent and at least one water-immiscible organic solvent. The polymer is selected to affect efficacy of the compositions. The compositions are essentially free of surface-active substances and have favorable galenic properties.

Abstract: A method for enhancing solubility of allantoin in an aqueous vehicle using a solubilization enhancer is described. Aqueous compositions containing the solubilized allantoin at a level of 0.5% by weight or higher are able to be obtained by using urea or urea derivatives as the solubilization enhancer. The aqueous topical compositions are suitable for cosmetic, dermatological, and pharmaceutical use.

Abstract: A method for enhancing solubility of allantoin in a non-aqueous pharmaceutically acceptable alcohol carrier using a solubilization enhancer is described. Non-aqueous compositions containing the solubilized allantoin at the FDA-approved levels of 0.5% to 2% by weight are able to be obtained by using urea or urea derivatives as the solubilization enhancer. The non-aqueous topical composition is suitable for cosmetic, dermatological, and pharmaceutical use.

Abstract: Disclosed is a platelet additive solution (PAS) comprising a viscosity increasing agent. The use of a PAS comprising such a viscosity increasing agent, especially at concentrations effective to achieve a viscosity similar to that of blood plasma, promotes platelet recovery during extraction from pooled buffy coats and provides for easier platelet production by maintaining the red cell/platelet-rich-supernatant interface.

Abstract: This invention relates to a method for topically treating dermal disorders employing a composition comprising a mixture of urea and a safe and effective amount of an alkyl urea in a therapeutically effective ratio. The urea and alkyl urea are blended with a carrier suitable for topical application to dermal tissues. The carrier is in the form of an aqueous liquid, a gel, a cream, a foam, a liposome, a nonaqueous liquid, a nonaqueous gel, or a nonaqueous cream.